Development of antinuclear antibody in patients treated with high doses of captopril
- 1 May 1984
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 27 (5) , 579-581
- https://doi.org/10.1002/art.1780270516
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Captopril‐Induced Skin EruptionsThe Journal of Clinical Pharmacology, 1982
- Hydralazine, antinuclear antibodies, and the lupus syndrome.BMJ, 1982
- Acetylator phenotype in idiopathic systemic lupus erythematosusArthritis & Rheumatism, 1980
- HYDRALAZINE-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS: INFLUENCE OF HLA-DR AND SEX ON SUSCEPTIBILITYPublished by Elsevier ,1980
- Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patientsProgress in Cardiovascular Diseases, 1978
- Effect of Acetylator Phenotype on the Rate at Which Procainamide Induces Antinuclear Antibodies and the Lupus SyndromeNew England Journal of Medicine, 1978
- Disease and Acetylation PolymorphismClinical Pharmacokinetics, 1977
- Acetylator Phenotype in Patients with Hydralazine‐induced Lupoid SyndromeActa Medica Scandinavica, 1976
- Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritisThe American Journal of Medicine, 1973